Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients.

Alejandro Morales-Ortega,Ana Isabel Farfán-Sedano,Aida Izquierdo-Martínez,Cristina Llarena-Barroso,Beatriz Jaenes-Barrios,Nieves Mesa-Plaza,María Toledano-Macías,Guillermo Soria Fernández-Llamazares, Laura Molina-Esteban,Jaime García de Tena,Santiago Prieto-Menchero,Sonia Gonzalo-Pascua,Juan Víctor San Martín-López,David Bernal-Bello

The Journal of infection（2021）

引用 1|浏览5

暂无评分

摘要

•Imatinib has been proposed as a potential treatment for COVID-19.•BCR-Abl inhibitors might interfere with humoral immunity.•IgG synthesis after COVID-19 is not impaired by a short course of imatinib.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要